Cell Therapy Technologies Market by Product (Media, Sera, and Reagents; Cell Engineering Products; Cell Culture Vessels; Cell Therapy Equipment; Cell Processing Equipment; Single-Use Equipment; Other), Process (Cell Processing; Cell Preservation, Distribution, and Handling; and Process Monitoring and Quality Control), Cell Type (T-Cells; Stem Cells; and other), End User (Biopharmaceutical and Biotechnology Companies; CROs and CMOs, Research Institutes and Cell Banks): Global Market Size Estimates and Forecast (2022-2030)

Code: BMIRE00026458 | Pages: 100 | Industry: Biotechnology | Date: Sep 2022 | Type: Global

The market crossed the US$ 14.66 billion mark in 2022 and is expected to hit US$ 33.38 billion by 2030, recording a CAGR of 10.1% during the forecast period.

Rising adoption of pluripotent cells for drug discovery and research.

iPSCs can be used for diverse programs, which include improving regenerative medicine and drug discovery and lowering the overall cost of medical trials. Pluripotent cells have shown promising results for Alzheimer's and other neurological degenerative diseases, as drug discovery for such diseases remains challenging. The drug discovery can be improved if the actual human cells are provided for an accurate understanding of the physiology, and drug efficiency can be easily evaluated. Human-induced pluripotent cells have opened a new path for research, disease modeling, and drug discovery. Patient-derived iPcs help improves results for phenotypic diseases as the phenotypic is similar to the disease. Additionally, this can create disease-specific assays due to its ability to differentiate into various cells as it holds multiple benefits, such as identifying somatic cell mutations, i.e., sporadic diseases.

Within the report, the market is segmented into product, process cell type, and end user. By product, the market is segmented into media, sera, and reagents; cell engineering products; cell culture vessels; cell therapy equipment; cell processing equipment; single-use equipment; and other. By process, the market is segmented into cell processing, cell preservation, distribution and handling, and process monitoring and quality control. By cell type, the market is segmented into t-cells, stem cells, and other. By end user, it is segmented into biopharmaceutical & biotechnology companies, CROs & CMOs, research institutes, & cell banks. Geographically, the market is sub-segmented into North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa.

Get more information on this report :

Rising adoption of cell therapy in pharmaceutical companies for drug discovery and development

Cell therapy is additionally popularly known as cellular therapy or cryotherapy. This therapy is often defined as a type of biotherapy especially utilized for the development of different drugs and therapeutic strategies that are cells based. Cell therapy is defined as a group of biological activities performed by cells to achieve the desired result in either in vitro or in vivo conditions.

Over the past few years, there has been considerable growth in determining the range and number of appropriate cell types for exterior administration. Interestingly, these cells have demonstrated favorable healing capabilities in animal-based experiments for various health conditions. Within the process of cell therapy, cell suspensions penetrate the bloodstream, a tissue, or an organ with a likelihood of those cells being able to help heal any injury.

The rising prevalence of HIV worldwide and promising results shown by stem cell therapy will propel the cell therapy market

WHO estimated a human immunodeficiency virus (HIV) prevalence of 37.7 million people by 2020, with recorded 680,000 deaths. Globally, HIV has claimed 36.3 million lives thus far. The evolution of somatic cell research and the conduction of applied clinical trials has discovered the high expectations of stem cell therapy in various medical conditions. Human immunodeficiency virus (HIV) infection may be a significant global public health issue. Despite this, the only treatment available in the mainstay is antiretroviral therapy. This treatment isn't curative, it must be used lifelong, and there are many issues with compliance and side effects.

 In recent years, somatic cell therapy has shown promising results in HIV management and can seriously impact the future of HIV treatment and prevention. The thought behind anti-HIV hematopoietic stem/progenitor cell (HSPC)-directed gene therapy is to genetically engineer patient-derived (autologous) HSPC to acquire an inherent resistance to HIV infection. Multiple stem-cell-based gene therapy strategies are suggested that may infer HIV resistance, including anti-HIV gene reagents and combinatorial gene strategies, giving rise to anti-HIV gene-modified HSPCs. Such stem cells can hamper HIV progression within the body by interrupting key stages of HIV proliferation. HIV type 1 can remain dormant in a cluster of differentiated cells in lymphocytes, and macrophages stem cell therapy holds the capacity to eliminate the viral genome from the dormant stage either by gene editing or cytotoxic antiviral cells. Such promising treatment for HIV by stem cell therapy will propel the market.

Recent strategic developments in the cell therapy technologies market

The cell therapy technologies market has undergone several significant consequences, and a few of these have been mentioned below:

  • In January 2021, Thermo Fisher Scientific launched the primary T-cell medium explicitly designed for allogeneic cell therapy workflows. The Gibco CTS OpTmizer Pro Serum-Free Media (SFM) is a kind of media solution that targets the metabolism of the healthy donor cell, making it viable for allogeneic production of off-the-shelf cell therapies. It allows faster memory cell production, potentially enabling more scalable, cost-effective cell therapy manufacturing

 

  • In March 2020, Danaher acquired the Biopharma business from General Electric Company's Life Sciences division. The acquisition has led to the formation of a replacement business named Cytiva, a standalone operating company within Danaher's Life Sciences segment. The investment will bring highly talented teams together and highly innovative and industry-leading products in the company Danaher's life science portfolio

 

  • In June 2019, Sartorius opened its manufacturing operations site in Yauco, Puerto Rico. The location cost investment of up to US$ 100 Mn. The target of the new site is to cater to the needs of the U.S. market. This is strategic and operational expansion as the company holds high ambitions for the American market

Several players drive the cell therapy technologies market by implementing strategic activities such as investments, new launches, mergers & acquisitions, and partnerships. Sartorius AG; Danaher Corporation; Becton; Dickinson and Company; Thermo Fisher Scientific Inc.; OrganaBio, LLC; Avantor Inc.; Eppendorf S.E.; Miltenyi Biotec B.V. & Co. K.G.; Gpi Iberia; and SIRION Biotech GmbH.

The target audience for the report:

  • Raw material providers
  • Government bodies, such as regulating authorities and policymakers
  • Venture capitalists, private equity firms, and start-up companies
  • Research institutes, organizations, and consulting companies
  • Biopharmaceutical and Biotechnology Companies
  • Cell Banks
  • Contract research organizations (CROs)
  • Contract Manufacturing Organisations (CMOS )

Scope of the report:

In this report, the market has been segmented based on:

  • By Product
    • Media, Sera, and Reagents
    • Cell Engineering Products
    • Cell Culture Vessels
    • Cell Therapy Equipment
    • Cell Processing Equipment
    • Single-use Equipment
    • Other
  • By Process
    • Cell Processing
    • Cell Preservation, Distribution, and Handling
    • Process Monitoring and Quality Control
  • By Cell Type
    • T-cells
    • Stem Cells
    • Other
  • By End User
    • Biopharmaceutical and Biotechnology Companies
    • CROs and CMOs
    • Research Institutes and Cell Banks
  • Region
    • North America
    • Europe
    • Asia Pacific (APAC)
    • Middle East & Africa (MEA)
    • South & Central America (SCAM)
  • Companies profiled
    • Sartorius AG
    • Danaher Corporation
    • Becton, Dickinson, and Company
    • Thermo Fisher Scientific Inc.
    • Avantor Inc.
    • Eppendorf SE
    • Miltenyi Biotec B.V. & Co. KG
    • SIRION Biotech GmbH
    • OrganaBio, LLC
    • Gpi Iberia

Companies profiled
- Sartorius AG
- Danaher Corporation
- Becton, Dickinson, and Company
- Thermo Fisher Scientific Inc.
- Avantor Inc.
- Eppendorf SE
- Miltenyi Biotec B.V. & Co. KG
- SIRION Biotech GmbH
- OrganaBio, LLC
- Gpi Iberia

Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$2000
Site License
$3000
Enterprise License
$4000